NCT05907629 Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging
| NCT ID | NCT05907629 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-06-24 |
| Primary Completion | 2029-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-06-24 with a primary completion date of 2029-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
CAPTIVA-MRI is an observational multimodal MR imaging study that is ancillary to the CAPTIVA trial \[a 3-arm, double-blind Phase III trial conducted at approximately 115 StrokeNet sites randomizing patients with stroke attributed to 70-99% intracranial atherosclerotic stenosis (ICAS) to aspirin plus ticagrelor, clopidogrel, or rivaroxaban.\] The primary goal of this ancillary study is to determine if MRI biomarkers can potentially identify ICAS patients who fail best medical management. The CAPTIVA-MRI study leverages the CAPTIVA trial design and implementation to capture information that will inform and facilitate the next generation of ICAS trials and the management of patients with ICAS.
Eligibility Criteria
Inclusion Criteria: * Enrollment in the CAPTIVA trial: nondisabling symptomatic ischemic infarct stroke within 30 days secondary to 70-99% stenosis of the intracranial ICA, MCA, BA or VA * Ability to obtain baseline study MRI within 14 days of CAPTIVA enrollmen Exclusion Criteria: * Unable or unwilling to undergo MRI, including pacemaker or other MRI contraindications per American College of Radiology guidelines62 * Gadolinium contrast allergy or acute or chronic kidney disease with eGFR\<30 ml/min/1.73m2
Contact & Investigator
David Liebeskind, MD
PRINCIPAL INVESTIGATOR
University of California, Los Angeles
Frequently Asked Questions
Who can join the NCT05907629 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05907629 currently recruiting?
Yes, NCT05907629 is actively recruiting participants. Contact the research team at ka-ho.wong@hsc.utah.edu for enrollment information.
Where is the NCT05907629 trial being conducted?
This trial is being conducted at Birmingham, United States, Aurora, United States, Hartford, United States, New Haven, United States and 11 additional locations.
Who is sponsoring the NCT05907629 clinical trial?
NCT05907629 is sponsored by Yale University. The principal investigator is David Liebeskind, MD at University of California, Los Angeles. The trial plans to enroll 300 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.